Pharmacogenetics of obsessive-compulsive disorder: Investigations of intragenic and regulatory region genetic variations.
Journal: Progress in neuro-psychopharmacology & biological psychiatry
Volume:
Issue:
Year of Publication:
Affiliated Institutions:
Neurogenetics Section, Centre for Addiction and Mental Health, Toronto, ON MT R, Canada; Department of Psychiatry, University of Toronto, Toronto, ON MT R, Canada; Institute of Medical Science, University of Toronto, Toronto MS A, Canada. Electronic address: gwyneth.zai@camh.ca.
Neurogenetics Section, Centre for Addiction and Mental Health, Toronto, ON MT R, Canada; Department of Psychiatry, University of Toronto, Toronto, ON MT R, Canada; Institute of Medical Science, University of Toronto, Toronto MS A, Canada; Laboratory Medicine and Pathobiology, University of Toronto, ON MS A, Canada; Harvard T. H. Chan School of Public Health, Huntington Ave., Boston, MA , USA; Stanley Center for Psychiatric Research, Broad Institute, Ames Street, Cambridge, MA , USA. Electronic address: clement.zai@camh.ca.
Neurogenetics Section, Centre for Addiction and Mental Health, Toronto, ON MT R, Canada; Department of Psychiatry, University of Toronto, Toronto, ON MT R, Canada. Electronic address: vanessa.goncalves@camh.ca.
The Frederick W. Thompson Anxiety Disorders Centre, Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON MN M, Canada. Electronic address: karen.wigg@sunnybrook.ca.
SA MRC Unit on Risk and Resilience in Mental Disorders, Department of Psychiatry, Stellenbosch University, South Africa. Electronic address: cl@sun.ac.za.
SA MRC Unit on Risk and Resilience in Mental Disorders, Department of Psychiatry and Neuroscience Institute, University of Cape Town, South Africa. Electronic address: dan.stein@uct.ac.za.
Department of Psychiatry, Center for OCD, Anxiety and Related Disorders, and Genetics Institute, University of Florida, United States. Electronic address: carolmathews@ufl.edu.
Neurogenetics Section, Centre for Addiction and Mental Health, Toronto, ON MT R, Canada; Department of Psychiatry, University of Toronto, Toronto, ON MT R, Canada; Institute of Medical Science, University of Toronto, Toronto MS A, Canada. Electronic address: jim.kennedy@camh.ca.
Department of Psychiatry, University of Toronto, Toronto, ON MT R, Canada; Institute of Medical Science, University of Toronto, Toronto MS A, Canada; The Frederick W. Thompson Anxiety Disorders Centre, Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON MN M, Canada. Electronic address: peggy.richter@sunnybrook.ca.
Abstract summary
Few pharmacogenetic studies on the use of genetic variations to predict antidepressant response in obsessive-compulsive disorder (OCD) have been published. This study expanded on the limited literature on single nucleotide polymorphisms (SNPs) across previously identified putative susceptibility genes for OCD, by incorporating known functional regulatory elements for all genes of interest. We investigated 17 SNPs in 12 genes implicated in OCD risk in 206 European ancestry OCD patients with selective serotonin reuptake inhibitor (SSRI) antidepressant response data, examining functional polymorphisms in remote regulatory regions. No association was observed between any regulatory region markers tested and drug response. We observed nominally significant associations between SNPs within the serotonin 1B receptor (5HT1B; SNP rs1778258), SLIT and NTRK-like family member 5 (SLITRK5; SNP rs10450811), and fas apoptotic inhibitory molecule 2 (FAIM2; SNP rs706795), with response to any SSRI, which did not survive multiple comparisons. This study supports a potential role for a number of OCD-associated risk genes in response to antidepressant treatment, warranting further investigation.
Authors & Co-authors:
Zai Gwyneth G
Zai Clement C CC
Gonçalves Vanessa F VF
Wigg Karen K
Lochner Christine C
Stein Dan J DJ
Mathews Carol A CA
Kennedy James L JL
Richter Margaret A MA
Study Outcome
Source Link: Visit source